Latest gastrointestinal stromal tumor Stories
EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking GleevecÂ® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment.
SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S.
WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.
TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma. The pivotal Phase III study will evaluate as the primary endpoint...
WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S.
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.
NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.